|Description||Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Phase 3.|
LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclin...
Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Phase 3.
BAR502 is a dual FXR and GPBAR1 agonist (IC50= 2 μM and 0.4 μM for FXR and GPBAR1, respectively).
Fexaramine is a small molecule farnesoid X receptor agonist with 100-fold increased affinity relative to natural compounds.
Turofexorate Isopropyl is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist.
PX-102, also known as PX-20606, is a farnesoid X-activated receptor (FXR) agonist. PX-102 is indicated to be active in lowering plasma cholesterol, and ameliora...
Chenodeoxycholic Acid is a naturally occurring human bile acid.Chenodeoxycholic acid has been used as medical therapy to dissolve gallstones.
EP-024297 is a novel agonist of farnesoid X receptor (FXR). Study in Chinese hamster ovary cells showed that it is 20000-fold more potent than obeticholic acid ...
Z-Guggulsterone is a broad spectrum steroid receptor ligand that acts as a mineralocorticoid, progesterone and glucocorticoid receptor antagonist (Ki = 37, 224 ...
DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7...
PX 20350 is a farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FX...
PX102 is a Farnesoid X-activated Receptor (FXR) agonist originated by Phenex Pharmaceuticals. PX102 demonstrated potent plasma cholesterol-lowering activity tha...
GW4064 is a selective non-steroidal agonist of farnesoid X receptor (FXR) with EC50 value of 15 nM.
Tropifexor is a novel highly potent agonist of farnesoid X receptor (FXR), which regulates bile acid metabolism and signaling. FXR activated by Tropifexor can i...
INT-767, a steride compound, has been found to be a inhibitor of FXR and TGF5 and could have probable effect against some liver and metabolic diseases. It was j...